Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CHI H, Hansen BE, Guo S, Zhang NP, et al
    Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    J Infect Dis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. CHEN GJ, Lin KY, Hung CC, Chang SC, et al
    Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  3. WANG L, Wen J, Gao F, Hao H, et al
    Hepatitis E virus-associated neurological injury in China.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  4. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  5. HAN Y, Gu L, Liu J, Li X, et al
    Association of mutations in TLR2 signaling genes with fulminant form of hepatitis B related acute liver failure.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. ZHOU X, Huang F, Xu L, Lin Z, et al
    Hepatitis E virus infects neurons and brains.
    J Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


    January 2017
  7. CAO J, Chi H, Yu T, Li Z, et al
    Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    J Infect Dis. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  8. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  9. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. CHEN MH, Chen MH, Liu CY, Tsai CY, et al
    Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment.
    J Infect Dis. 2016 Dec 23. pii: jiw606. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  12. SCHIRDEWAHN T, Grabowski J, Sekyere SO, Bremer B, et al
    The third signal cytokine IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  13. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  14. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  15. WANG L, Wiener J, Bulterys M, Wei X, et al
    Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  16. HONER ZU SIEDERDISSEN C, Rinker F, Maasoumy B, Wiegand SB, et al
    Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  17. MAYORGA O, Buhler S, Jaeger VK, Bally S, et al
    Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  18. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  19. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  20. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  21. ZEREMSKI M, Dimova RB, Pillardy J, de Jong YP, et al
    Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  22. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    June 2016
  23. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  24. BEHRENDT P, Bremer B, Todt D, Brown RJ, et al
    Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  25. SHILAIH M, Marzel A, Scherrer AU, Braun DL, et al
    Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  26. SIMONS BC, Spradling PR, Bruden DJ, Zanis C, et al
    A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B cellular immunity despite loss of antibody against hepatitis B surface antigen.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  27. HONDA M, Shirasaki T, Terashima T, Kawaguchi K, et al
    Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    J Infect Dis. 2016;213:1096-106.
    PubMed     Text format     Abstract available


    March 2016
  28. MOQUEET N, Cooper C, Gill J, Hull M, et al
    Responder Interferon Lambda genotypes are associated with higher risk of liver fibrosis in HIV-Hepatitis C Virus Co-infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  29. ARAGRI M, Alteri C, Battisti A, Di Carlo D, et al
    Multiple HBV Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  30. EVANS TI, Li H, Schafer JL, Klatt NR, et al
    SIV-induced Translocation of Bacterial Products in the Liver Mobilizes Myeloid Dendritic and Natural Killer Cells Associated With Liver Damage.
    J Infect Dis. 2016;213:361-9.
    PubMed     Text format     Abstract available


    January 2016
  31. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  32. BRUCE MG, Bruden D, Hurlburt D, Zanis C, et al
    Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  33. SAKIANI S, Koh C, Heller T
    Reply to Tennant and Post.
    J Infect Dis. 2016;213:325-6.
    PubMed     Text format    


  34. PIROTH L, Launay O, Michel ML, Bourredjem A, et al
    Vaccination against hepatitis B virus in HIV-1 infected patients with isolated anti-HBc: the ANRS HB EP03 CISOVAC prospective study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  35. MASTRO TD, Morrison CS, Hamilton CD
    Determining Hepatitis C Virus Incidence in Populations: an Important Tool for Epidemic Control.
    J Infect Dis. 2016.
    PubMed     Text format    


  36. PATEL EU, Cox AL, Mehta SH, Boon D, et al
    Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  37. MATTHEWS PC, Carlson JM, Beloukas A, Malik A, et al
    HLA-A is a Predictor of Hepatitis B e-Antigen Status in HIV-positive African Adults.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  38. SWANSON S, Ma Y, Scherzer R, Huhn G, et al
    Association of HIV, HCV and Liver Fibrosis Severity with the Enhanced Liver Fibrosis Score.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  39. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  40. LIANG KH, Hsu CW, Chang ML, Chen YC, et al
    Peginterferon is superior to nucleos(t)ide analogs for prevention of hepatocellular carcinoma in chronic hepatitis B.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  41. OLMSTEAD AD
    Digging Deeper into Hepatitis C Virus Outbreaks.
    J Infect Dis. 2015.
    PubMed     Text format    


  42. CAMPO DS, Xia GL, Dimitrova Z, Lin Y, et al
    Accurate genetic detection of hepatitis C virus transmissions in outbreak settings.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  43. CHANG A, Chen Y, Shen W, Gao R, et al
    Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway.
    J Infect Dis. 2015;212:1509-20.
    PubMed     Text format     Abstract available


  44. MORON-LOPEZ S, Gomez-Mora E, Salgado M, Ouchi D, et al
    Short-term treatment with IFNalpha diminishes expression of HIV-1 and reduces CD4+ T-cell activation in HIV/HCV-coinfected patients on antiretroviral therapy.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  45. WANDRER F, Falk C, John K, Skawran B, et al
    Interferon-mediated cytokine induction determines sustained virus control in chronic HCV infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  46. JONES T
    Comment on Ly and Klevens, Trends in Disease and Complications of Hepatitis A Virus Infection.
    J Infect Dis. 2015.
    PubMed     Text format    


  47. LY KN, Klevens RM, Jiles RB
    Reply to Jones.
    J Infect Dis. 2015.
    PubMed     Text format    


    September 2015
  48. MARTINI H, Citro A, Martire C, D'Ettorre G, et al
    Apoptotic epitope-specific CD8+ T cells and interferon signaling intersect in chronic hepatitis C virus infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  49. NELSON KE
    Reply to Ly et al.
    J Infect Dis. 2015;212:1010.
    PubMed     Text format    


  50. SOULIER A, Poiteau L, Rosa I, Hezode C, et al
    Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis and treatment monitoring.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  51. THURSZ M, Lacombe K
    Breaking down barriers to care in Hepatitis C Virus infection.
    J Infect Dis. 2015.
    PubMed     Text format    


    August 2015
  52. RYBCZYNSKA J, Campbell K, Kamili S, Locarnini S, et al
    CD4+ T Cells Are Not Required for Suppression of Hepatitis B Virus Replication in the Liver of Vaccinated Chimpanzees.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  53. TENNANT E, Post JJ
    The Production of False Positive IgM Antibodies to Hepatitis A in Autoimmune Events.
    J Infect Dis. 2015.
    PubMed     Text format    


    July 2015
  54. SPAAN M, van Oord G, Kreefft K, Hou J, et al
    Immunological analysis during IFN-free therapy for chronic HCV reveals modulation of the NK cell compartment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  55. JANSEN L, Kootstra NA, van Dort KA, Takkenberg RB, et al
    Hepatitis B Pregenomic RNA is Present in Virions in Plasma and is Associated With Response to Peginterferon and Nucleos(t)ide Analogues.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  56. MCKIBBEN RA, Haberlen SA, Post WS, Brown TT, et al
    Chronic Hepatitis C Virus Infection Is Associated with Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS): a Cross-Sectional Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  57. ZHOU N, Hernandez D, Ueland J, Yang X, et al
    NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  58. HERMANS LE, Svicher V, Pas SD, Salpini R, et al
    Combined Analysis of the Prevalence of drug Resistant HBV in antiviral therapy Experienced patients in Europe (CAPRE).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    June 2015
  59. GANOVA-RAEVA L, Punkova L, Campo DS, Dimitrova Z, et al
    Cryptic Hepatitis B and E in Patients With Acute Hepatitis of Unknown Etiology.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    May 2015
  60. LIU XE, Chen HY, Liao Z, Zhou Y, et al
    Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    April 2015
  61. BOLTJES A, van Montfoort N, Biesta PJ, Op den Brouw ML, et al
    Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function.
    J Infect Dis. 2015;211:1268-78.
    PubMed     Text format     Abstract available


    November 2014
  62. LANTERI MC, Vahidnia F, Tan S, Stapleton JT, et al
    Downregulation of cytokines and chemokines by GB virus C after transfusion-transmission in HIV+ blood recipients.
    J Infect Dis. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: